The Chronic Lymphocytic Leukemia Antigen (cCLLa) as Immunotherapy Target: Pharmacokinetics and Biodistribution of Two Divalent, Ricin-Based Immunotoxins in Xenografted Athymic Mice

References

• Foon K. A., Schroff R. W., Bunn P. A., Mayer D., Abrams P. G., Fer M., Ochs J., Bottino G. C., Sherwin S. A., Carlo D. J., et al. Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia. Blood 1984; 64: 1085
   PubMed Web of Science ®Google Scholar
• Meeker T. C., Lowder J., Maloney D. B., Miller R. A., Thielmans K., Warnke R., Levy R. A clinical trial of anti‐idiotype therapy for B‐cell malignancy. Blood 1985; 65: 1349
   PubMed Web of Science ®Google Scholar
• Janson D., Nissel‐Horowitz S., Sattler M., Rai K. R. Complete and partial response in treatment of advanced refractory B‐cell chronic lymphocytic leukemia using CAMPATH‐1H. Blood 1993; 82: 139a, abstract
   PubMed Web of Science ®Google Scholar
• Vitetta E. S., Fulton R. J., May D., Till M., Uhr J. W. Redesigning nature's poisons to create anti‐tumor reagents. Science 1987; 238: 1098
   PubMed Web of Science ®Google Scholar
• Pastan I., Willingham M. C., Fitzgerald D. J. Immunotoxins. Cell 1986; 47: 641
   PubMed Web of Science ®Google Scholar
• Vitetta E. S., Stone M., Amlot P., Fay J., May R., Till M., Newman J., Clark P., Collins R., Cunningham D., Ghetie V., Uhr J. W., Thorpe P. E. Phase I immunotoxin trial in patients with B‐cell lymphoma. Cancer Res. 1991; 54: 4052
   Google Scholar
• Faguet G. B., Agee J. F. Four ricin chain A‐based immunotoxins directed against the common chronic lymphocytic leukemia antigen: In vitro characterization. Blood 1993; 82: 536
   PubMed Web of Science ®Google Scholar
• Moazed D., Robertson J., Noller H. Interaction of elongation factors EF‐G and EF‐Tu with a conserved loop in 23S RNA. Nature 1992; 334: 362
   Web of Science ®Google Scholar
• Middlebrook J., Dorlan R. Bacterial toxin: Cellular mechanisms of action. Microbiol. Rev. 1984; 48: 199
   PubMedGoogle Scholar
• Hertler A. A., Schlossman D. M., Borowitz M. J., Blythman H. E., Casellas P., Frankel A. E. An anti‐CD5 immunotoxin for chronic lymphocytic leukemia: enhancement of cytotoxicity with human serum albumin‐monensin. Int. J. Cancer 1989; 43: 215
   PubMed Web of Science ®Google Scholar
• Hertler A. A., Schlossman D. M., Borowitz M. J., Laurent G., Jansen F. K., Schmidt C., Frankel A. E. A phase I study of TlOl‐ricin A chain immunotoxin in refractory chronic lymphocytic leukemia. J. Biol. Resp. Modif. 1988; 7: 97
   PubMedGoogle Scholar
• LeMaistre F., Deisseroth A., Fogel B., Meneghetti C., Anderson J. M., Saria E., Lomen P., Byers V. Phase I trial of H65–RTA in patients with chronic lymphocytic leukemia. Blood 1990; 76: 295a, abstract
   Google Scholar
• Dillman R. O., Shwaler J. B., Royston I. Therapy of chronic lymphocytic leukemia and cutaneous T‐cell lymphoma with 101 monoclonal antibody. J. Clin. Oncol. 1984; 2: 881
   PubMed Web of Science ®Google Scholar
• Dillman R. O., Beauregard D. L., Shawler J. B., Halpem S. E., Markman M., Ryan K. P., Baird S. M., Cluter M. Continuous infusion of T101 monoclonal antibody in chronic lymphocytic leukemia and cutaneous T‐cell lymphoma. J. Biol. Resp. Modif. 1986; 5: 394
   PubMedGoogle Scholar
• Grossbard M. L., Freedman S. A., Ritz J., Coral F., Goldmacher V. S., Eliseo L., Spector N., Dear K., Lambert J. M., Blatter W. A., et al. Serotherapy of B‐CLL neoplasms with anti‐B4‐blocked ricin: A phase I trial of daily bolus infusion. Blood 1992; 79: 576
   PubMed Web of Science ®Google Scholar
• Derocq J. M., Casellas P., Laurent G., Ravel S., Vidal H., Jansen F. Comparison of the cytotoxic potency of T101 Fab. F(ab)2 and whole IgG immunotoxins. J. Immunol 1988; 141: 2837
   PubMed Web of Science ®Google Scholar
• Agee J. F., Garver F. A., Faguet G. B. An antigen common to chronic lymphocytic and hairy cell leukemia cells not shared by normal lymphocytes or other leukemic cells. Blood 1986; 68: 62
   PubMed Web of Science ®Google Scholar
• Faguet G. B., Agee J. F. Monoclonal antibodies against the chronic lymphocytic leukemia antigen cCLLa: characterization and reactivity. Blood 1987; 70: 437
   PubMed Web of Science ®Google Scholar
• Faguet G. B., Agee J. F., Marti G. E. CD5 and cCLLa expression in chronic lymphocytic leukemia (CLL): Demonstration of their relative prevalence ant that of other common B‐CLL markers. Leukemia & Lymphoma 1992; 6: 335
   Web of Science ®Google Scholar
• Faguet G. B., Agee J. F., Marti G. E. Clone emergence and evolution in chronic lymphocytic leukemia: Characterization of the clinical, laboratory and immunopheno‐typic profiles in 25 patients. Leukemia & Lymphoma 1992; 6: 345
   Web of Science ®Google Scholar
• Faguel G. B., Agee J. F. The chronic lymphocytic leukemia antigen (cCLLa) as immunotherapy target: assessment of LD50 and MTD of four ricin‐based anti‐cCLLa immunotoxins in Balb/c mice. Leukemia & Lymphoma 1997; 25: 531–537
   PubMed Web of Science ®Google Scholar
• Colapinto E. V., Hymphrey P. A., Zalutsky M. R. Comparative localization of murine monoclonal antibody Mel‐14 F(ab)′2 fragment and whole IgG2a in human glioma xenografts. Cancer Res. 1988; 48: 5701
   PubMed Web of Science ®Google Scholar
• Zhu Z., Ghose T., Iies S., Yang C., Lee S. H. Pharmacokinetics, biodistribution and tumor localization of two anti‐human B‐cell chronic lymphocytic leukemia monoclonal antibodies and their F(ab)′2 fragments in a xenograft model. Cancer Letters 1994; 76: 31
   PubMed Web of Science ®Google Scholar
• Faguet G. B., Agee J. F. Transplantation of human Hairy cell leukemia in radiation‐preconditioned nude mice: Characterization of the model by histological. histo‐chemical, phenotypic and tumor kinetic studies. Blood 1988; 71: 1511
   PubMed Web of Science ®Google Scholar
• Faguet G. B., Agee J. F. A simple technique for the rapid enrichment of class and subclass hybridoma switch variants: A 1000‐fold enrichment in half the time for half the cost. J. Immunol. Methods 1993; 165: 217
   PubMed Web of Science ®Google Scholar
• Hunter W., Greenwood F. C. Preparation of iodine‐131 labelled human growth hormone of high specific activity. Nature 1962; 194–495
   Google Scholar
• Fraker P. J., Speck C. J. Protein and cell membrane iodinations with a sparingly soluble chlomide 1, 3, 6‐tetrachloro‐3a, 6a‐diphenylglycouracil. Biochem. Biophys. Res. Commun. 1978; 80: 849
   PubMed Web of Science ®Google Scholar
• Bjorck L., Kronvall G. Purification and some properties of Streptococcal protein G: A novel IgG binding reagent. J. Immunol. 1984; 133: 969
   PubMed Web of Science ®Google Scholar
• Faguet G. B., Agee J. F., DiPiro J. T. Blood kinetics, tissue distribution and radioimaging of anti‐common chronic lymphatic leukemia antigen (cCLLa) monoclonal antibody CLL, in mice transplanted with cCLLa‐bearing human leukemia cells. Blood 1990; 75: 1853
   PubMed Web of Science ®Google Scholar
• Faguet G. B., Satya‐Prakash K. I., Agee J. F. Cytochemical, cytogenetic. immunophenotypic and tumori‐genic characterization of two hairy cell lines. Blood 1988; 71: 422
   PubMed Web of Science ®Google Scholar
• Fulton R. J., Tucker T. F., Vitetta E. S., Uhr J. W. Pharmacokinetics of tumor‐reactive immunotoxins in tumor‐bearing mice: Effect of antibody valency and deglyco‐sylation of the ricin A chain on clearance and tumor localization. Cancer Res. 1988; 48: 2618
   PubMed Web of Science ®Google Scholar
• Blakey D. C., Watson G. J., Knowles P. P., Thorpe P. E. Effect of chemical deglycosylation of ricin A chain on the in vivo fate and cytotoxic activity of an immunotoxin composed of ricin A chain and anti‐Thy‐1.1 antibody. Cancer Res. 1987; 47: 947
   PubMed Web of Science ®Google Scholar
• Worrell N. R., Cumber A. J., Parnell G. D., Ross W. C. J., Forrester J. A. Fate of an antibody‐ricin A conjugate administered to normal rats. Biochem. Pharmacol 1986; 35: 417
   PubMed Web of Science ®Google Scholar
• Bourrie B. J. P., Casellas P., Blythman H. E., Jansen J. K. Study of the plasma clearance of antibody ricin‐A chain immunotoxins. Evidence for specific recognition sites on the A chain that mediate rapid clearance of the immunotoxin. Eur. J. Biochem. 1986; 155: 1
   PubMedGoogle Scholar
• Thorpe P. E., Detre S. I., Foxwell B. M., Brown A. N. F., Skilleter D. N., Wilson G., Forrester J. A., Stirpe F. Modifications of the carbohydrate in ricin with meta‐periodate‐cyanoborohydride mixtures, Effects on toxicity and in vivo distribution. Eur. J. Biochem. 1985; 147: 197
   PubMedGoogle Scholar
• Schlesinger P. H., Doebber T. W., Mandell B. F., White R., SeSchryver C., Rodman J. S., Miller M. J., Stahl P. Plasma clearance of glycoproteins with terminal man‐nose and N‐acetylglucosamine by liver non‐parenchymal cells. Studies with β‐D‐glucosaminidase ribonuclease B and galacto‐orosomucoid. Biochem. J. 1978; 176: 103
   PubMed Web of Science ®Google Scholar
• Ramakrishnan S., Houston L. L. Immunological and biological stability of immunotoxins in vivo as studied by the clearance of disulfide‐linked pokeweed antiviral protein‐antibody conjugates from blood. Cancer Res. 1985; 45: 2031–2036
   PubMed Web of Science ®Google Scholar
• Faguet G. B., Agee J. F. Modulation, shedding and serum titers of the chronic lymphocytic leukemia‐associated antigen: Characterization and clinical correlations. Blood 1989; 74: 2493
   PubMed Web of Science ®Google Scholar